



FOR IMMEDIATE RELEASE

Jounce Therapeutics Appoints Duncan Higgons to Its Board of Directors

Cambridge, Mass., November 17, 2015 – Jounce Therapeutics, Inc., a company focused on the discovery and development of cancer immunotherapies coupled to patient selection strategies, today announced that biopharmaceutical industry veteran Duncan Higgons has been appointed to the company’s board of directors.

“We are thrilled to welcome Duncan to our board of directors,” said Richard Murray, Ph.D., chief executive officer of Jounce. “His extensive experience leading companies from discovery to development to commercialization of drug candidates will be a tremendous asset to Jounce as we continue to grow and move our products candidates forward.”

Mr. Higgons has served as the chief operating officer at Agios Pharmaceuticals since 2009. In this role, he has been integral to the company’s continued expansion and has led key business negotiations and other operational functions. Prior to joining Agios, Mr. Higgons served as executive vice-president, and interim president and chief executive officer at Archemix Corporation from 2006 to 2009. Prior to Archemix, Mr. Higgons served as the chief commercial officer at TransForm Pharmaceuticals, Inc., a privately-held biotechnology company, which was acquired by Johnson & Johnson Company. Mr. Higgons holds a B.Sc. in mathematics from King's College University in London and a M.Sc. in economics from London Business School.

“Jounce is developing a leading immuno-oncology program through a truly differentiated approach that I believe sets them apart from others in the industry,” said Mr. Higgons. “I am delighted to join the company’s board of directors as the team moves closer to translating this science into potentially important new treatments for patients with cancer.”

About Jounce Therapeutics

Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce integrates translational science insights to select the right targets and patient populations leading to clinical trials with higher probability of success and rapid proof-of-concept. The company is advancing programs that leverage contributions from its world-class founders as well as knowledge acquired from Jounce’s translational science platform to create a sustainable “discovery to human proof-of-concept” product engine with the potential to drive significantly more durable responses to treatment. Founded by world leaders in tumor immunology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in



2013 with funding from leading life sciences investor, Third Rock Ventures. For more information, please visit www.jouncetx.com.

Media Contact:

Dan Budwick

Pure Communications, Inc.

(973) 271-6085

dan@purecommunicationsinc.com

###